

Oxygen Uptake and Carbon Dioxide Elimination during Epinephrine-induced Arrhythmias in Humans

Yoshito SHIRAISHI, Yoshiki NAKAJIMA,
Jun-ichirou YOKOYAMA and Kazuyuki IKEDA*

(Key words: cardiac arrhythmias, oxygen uptake, carbon dioxide elimination)

Halothane sensitize the myocardium to exogenous catecholamines. Many cases of epinephrine-induced arrhythmias during halothane anesthesia¹⁻⁵ have been reported, but there is no reports regarding minute oxygen uptake ($\dot{V}O_2$), or minute carbon dioxide elimination ($\dot{V}CO_2$) during epinephrine-induced arrhythmias.

This case report is interesting for the following reasons: $\dot{V}O_2$ and $\dot{V}CO_2$ increased suddenly during accidental epinephrine-induced arrhythmias and prostaglandin E₁ (PGE₁) might suppress myocardial irritability.

The causes of the increase in $\dot{V}O_2$ and $\dot{V}CO_2$ during epinephrine-induced arrhythmias and the protective mechanisms of PGE₁ against myocardium are discussed through this case.

Report of a case

The patient was a 68-year-old woman, whose height, weight, and body surface area (BSA) were 141 cm, 45 kg and 1.32 m², respectively.

Department of Anesthesia, Shizuoka General Hospital, Shizuoka, Japan

**Department of Anesthesiology, Hamamatsu University School of Medicine, Hamamatsu, Japan*

Address reprint requests to Dr. Shiraishi: Department of Anesthesia, Shizuoka General Hospital, 4-27-1 Kita-ando, Shizuoka, 420 Japan

She had a left breast cancer and underwent an extensive radical mastectomy and parasternal lymphnodes dissection. She had neither particular history nor systemic disease except hypertension.

Induced hypotension using PGE₁ was scheduled under nitrous oxide, oxygen, and halothane anesthesia. Since her usual systolic blood pressure was about 150 mmHg, 75-80% of her usual blood pressure (100-120 mmHg: systolic pressure) was intended for induced hypotension. For continuous blood pressure monitoring and analysis of blood gases a radial artery catheter was inserted.

Fifty ml of 0.9% saline solution containing epinephrine was administered locally for the purpose of hemostasis just before the incision. Arterial blood pressure increased suddenly and multifocal ventricular arrhythmias appeared when the surgery started. Therefore, the anesthetic agent was changed from halothane to enflurane. Its concentration was increased to 3.5% inspired (approximately 2 MAC) for deepening anesthesia and 40 mg of lidocaine was immediately injected intravenously against arrhythmias. However, her blood pressure continued to increase to 240 mmHg with ventricular tachycardia. The surgery was imme-

diately interrupted, and we confirmed the concentration of epinephrine administered to the patient was 1/5,000 instead of 1/500,000. Sixty mg of lidocaine was administered additionally, and 0.2–0.3 $\mu\text{g}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ of PGE₁, which had been prepared for induced hypotension and 1 $\text{mg}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ of lidocaine was infused simultaneously. The arrhythmias disappeared and the abnormally elevated blood pressure gradually decreased. In order to remove the influences of locally administered epinephrine as quickly as possible, the surgery was started again. The patient's blood pressure was kept at the level of about 110/60 mmHg with PGE₁. The urine output was maintained at more than 1 $\text{ml}\cdot\text{kg}^{-1}\cdot\text{hr}^{-1}$.

$\dot{V}\text{O}_2$ and $\dot{V}\text{CO}_2$ were measured continuously using a non-invasive Respiratory Anesthetic Metabolic Scanning Monitoring System (RAMSCAN[®])^{6,7} from the start of anesthesia to the end of anesthesia. The RAMSCAN consists of a mass spectrometer and a mini-mixing chamber (Bymixer)⁸. $\dot{V}\text{O}_2$ and $\dot{V}\text{CO}_2$ increased suddenly in accordance with blood pressure elevation. When the accident was occurred, $\dot{V}\text{O}_2$ increased two times transitorily and then 1.5 times for about 10 min. $\dot{V}\text{CO}_2$ also increased two times and this lasted about 10 min. During induced hypotension with PGE₁, $\dot{V}\text{O}_2$ and $\dot{V}\text{CO}_2$ were stable at the normal level. After the administration of PGE₁ was stopped, the blood pressure remained relatively stable, while $\dot{V}\text{O}_2$, $\dot{V}\text{CO}_2$ and R (gas exchange ratio) fluctuated remarkably. It suggested that her systemic metabolism was unstable. After emergence from anesthesia, no neurological sequelae were noticed and her postoperative course was uneventful.

Discussion

During halothane anesthesia, the maximum dose of 1/100,000 epinephrine solution is 0.15 $\text{mg}\cdot\text{kg}^{-1}$. The

amount which we planned to use for this case was 50 ml of 1/500,000 solution. Unfortunately, very severe arrhythmias, including multifocal ventricular dysrhythmia and ventricular tachycardia were induced by 10 mg of epinephrine accidentally.

It is considered that the increase in $\dot{V}\text{O}_2$ and $\dot{V}\text{CO}_2$ was caused by the increase in cardiac work as well as the increase in systemic metabolic rate caused by epinephrine.

Anesthesia itself has the protective effect against surgical stress and the administration of PGE₁ has a pharmaceutical effect in a significant decrease of the release of epinephrine from the adrenal gland besides vasodilatation^{10,11}. Since the plasma concentrations of catecholamines were not measured, it could not be explained why the patient's blood pressure remained stable though $\dot{V}\text{O}_2$ and $\dot{V}\text{CO}_2$ fluctuated after PGE₁ administration was stopped.

The increase in $\dot{V}\text{O}_2$ and $\dot{V}\text{CO}_2$ and severe arrhythmias induced by overdose of epinephrine were suppressed by deep enflurane anesthesia and continuous administration of PGE₁ and lidocaine.

Prostaglandin E₁ also has a coronary dilatory effect¹². PGE₁ may reduce coronary spasms¹².

PGE₁ increase myocardial oxygen supply, decrease myocardial oxygen consumption and markedly improves myocardial oxygen balance.

PGE₁ was used for vasodilatation in order to reduce afterload. PGE₁ has been known to antagonize epinephrine-induced arrhythmias⁹.

Nitroglycerin (TNG), beta-blockers, and calcium channel antagonists are also effective for treatment of dysrhythmia of various types. Nitroglycerin is a systemic venous vasodilator¹³, whereas PGE₁ is an arterial vasodilator¹⁴. Because of this latter effect interfering with epinephrine-

induced vasoconstriction, the administration of PGE_1 seemed to be reasonable for treatment of our case.

The mechanisms of suppression $\dot{V}O_2$ and $\dot{V}CO_2$ during administration of PGE_1 in our case may be due to a decrease in endogenous epinephrine secretion^{10,11}. Our case also show a protective effect of PGE_1 against epinephrine-induced ventricular irritability.

These effects were supported by the facts that metabolic parameters ($\dot{V}O_2$, $\dot{V}CO_2$ and R) were stable during PGE_1 -induced hypotension after epinephrine-induced arrhythmias.

This case report suggests that if massive doses of epinephrine is accidentally injected during anesthesia, ventricular irritability and an increase in $\dot{V}O_2$ and $\dot{V}CO_2$ can be suppressed by prostaglandin E_1 .

Appendix

The Respiratory Anesthetic Metabolic Scanning Monitoring System (RAMSCAN)^{7,8} which we use in our institute every day has following capacities. The mixing chamber (Bymixer)⁶ has a 90% response time capacity of 24.8 seconds (ventilation volume: 7.5 $l \cdot \text{min}^{-1}$). The mass spectrometer has a sampling time capacity of 15 seconds. Therefore, this system can correspond to the metabolic changes in a short span of time, that is within one minute.

Acknowledgment: The authors wish to thank Dr. Martha Lee Alexander, Native Professor of English, Hamamatsu University School of Medicine, for her grammatical advice in the preparation of this manuscript.

(Received Aug. 17, 1988, accepted for publication Oct. 9, 1991)

References

1. Katz RL, Bigger JT: Cardiac arrhythmias during anesthesia and operation. *Anesthesiology* 33:193-213, 1970
2. Joas TA, Stevens WC: Comparison of the arrhythmic doses of epinephrine during Forane, halothane, and fluroxene anesthesia in dogs. *Anesthesiology* 35:48-53, 1971
3. Johnston RR, Eger EI II, Wilson C: Comparative interaction of epinephrine with enflurane, isoflurane, and halothane in man. *Anesth Analg* 55:709-712, 1976
4. Imamura S, Ikeda K: Comparison of the epinephrine-induced arrhythmogenic effect of sevoflurane with isoflurane and halothane. *J Anesth* 1:62-68, 1987
5. Horrigan RW, Eger EI II, Wilson C: Epinephrine-induced arrhythmias during enflurane anesthesia in man: A nonlinear dose-response relationship and dose-dependent protection from lidocaine. *Anesth Analg* 57:547-550, 1978
6. Shiraishi Y, Yokoyama J, Karasawa H, et al: Measurement of uptake and elimination of volatile anesthetic agents - Use of respiratory and metabolic monitoring system (HOPE system). *J Jpn Soc Clin Anesth* 7:250-255, 1987
7. Sanjo Y, Ikeda K, Yura M, et al: Computer applications for respiratory data processing - Multipatient mass spectrometry and computer -. *J Int Care Med* 7:23-26, 1983
8. Sanjo Y, Ikeda K: A small bypass mixing chamber for monitoring metabolic rate and anesthetic uptake: the bymixer. *J Clin Monit* 3:235-243, 1987
9. Pace NL, Ohmura A, Wong KC: Epinephrine-induced arrhythmias: effect of exogenous prostaglandins and prostaglandin synthesis inhibition during halothane- O_2 anesthesia in dog. *Anesth Analg* 58:401-404, 1979
10. Boonyaviroj P, Gutman Y: a-Adrenergic stimulants, prostaglandins and catecholamine release from the adrenal gland in vitro. *Prostaglandins* 10:109-116, 1975
11. Gutman Y, Boonyaviroj P: Mechanism of PGE inhibition on catecholamine release from adrenal

- medulla. *Europ J Pharmacol* 55:129–136, 1974
12. Needleman P, Kaley G: Cardiac and coronary prostaglandin synthesis and function. *N Engl J Med* 298:1122–1128, 1978
13. Weiner R, Kaley G: Influence of prostaglandin E₁ on the terminal vascular bed. *Am J Physiol* 217:563–566, 1969
14. Panzenbeck MJ, Arsenio B, Kaley G: Nitroglycerin and nitroprusside increase coronary blood flow in dogs by a mechanism independent of prostaglandin release. *Am J Cardiol* 53:936–940, 1984